Synta Pharmaceuticals and Madrigal Pharmaceuticals have entered into a merger agreement under which Madrigal will become part of a Synta subsidiary. The combined company will focus on the development of novel small-molecule drugs addressing cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). Madrigal’s lead compound, MGL-3196, is a Phase 2-ready once-daily, oral, liver-directed selective thyroid hormone receptor-ß (THR-ß) agonist for the treatment of NASH and heterozygous...